Skip to content
lifestyle.buyersdesire.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jaguar Health, Inc.
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health’s Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
September 10, 2026
Neonorm Dog Now on Amazon: Jaguar Health Digestive Support
September 8, 2026
Additional Infant Patient to Receive Jaguar Health’s Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
September 4, 2026
Commercial Launch Initiated for Neonorm Dog, Jaguar Health’s Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
August 26, 2026
Jaguar Health Reports Second Quarter 2026 Financials
August 19, 2026
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
August 18, 2026
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
August 5, 2026
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
July 28, 2026
Additional Infant Patient to Receive Jaguar Health’s Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
July 22, 2026
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health’s Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
June 30, 2026
1
2
3
4
Next Page
→